Economic Modelling of Screen-and-Treat Strategies for Brazilian Women at Risk of Hereditary Breast and Ovarian Cancer
ConclusionAlthough there is no rigorous cost-effectiveness threshold in Brazil, the result of this cost-effectiveness analysis may support the inclusion ofBRCA1/2 testing for women at high-risk of cancer in the SUS. The ICER calculated for the provision of genetic testing forBRCA1/2 approximates the cost-effectiveness threshold proposed by the World Health Organization (WHO) for low- and middle-income countries.
Source: Applied Health Economics and Health Policy - Category: Health Management Source Type: research
More News: Brazil Health | Cancer | Cancer & Oncology | Economics | Genetics | Health Management | International Medicine & Public Health | Mastectomy | Ovarian Cancer | Ovaries | Study | WHO | Women